Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Knight Therapeutics Inc (GUD.TO)

Knight Therapeutics Inc (GUD.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 1,038,919
  • Shares Outstanding, K 135,629
  • Annual Sales, $ 12,500 K
  • Annual Income, $ 24,079 K
  • 60-Month Beta 0.63
  • Price/Sales 76.44
  • Price/Cash Flow N/A
  • Price/Book 1.08
  • Price/Earnings ttm 50.07
  • Earnings Per Share ttm 0.15
  • Most Recent Earnings -0.02 on 09/30/19
  • Next Earnings Date 11/12/19
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Indices Health Care

    TSX Indices Composite

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.01
  • Number of Estimates 3
  • High Estimate 0.05
  • Low Estimate -0.05
  • Prior Year 0.04
  • Growth Rate Est. (year over year) -75.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.53 +0.66%
on 11/20/19
8.88 -14.64%
on 10/23/19
+0.07 (+0.93%)
since 10/18/19
3-Month
7.32 +3.55%
on 10/04/19
8.88 -14.64%
on 10/23/19
-0.18 (-2.32%)
since 08/20/19
52-Week
7.10 +6.76%
on 05/03/19
8.88 -14.64%
on 10/23/19
-0.92 (-10.82%)
since 11/20/18

Most Recent Stories

More News
Knight Therapeutics Reports Third Quarter 2019 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2019. All currency amounts are in...

KHTRF : 5.6600 (-1.91%)
GUD.TO : 7.58 (-1.04%)
Notice of Knight Therapeutics' Third Quarter 2019 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, will release its third quarter 2019 financial results on Tuesday, November 12, 2019 after market closing....

KHTRF : 5.6600 (-1.91%)
GUD.TO : 7.58 (-1.04%)
Knight and TherapeuticsMD Announce Filing of New Drug Submission for Joyesta(TM) in Canada

Knight Therapeutics Inc. (TSX: GUD) ("Knight") and TherapeuticsMD, Inc. (NASDAQ: TXMD) ("TherapeuticsMD") announced today that Knight's New Drug Submission (NDS) for Joyesta(TM) has been accepted for review...

KHTRF : 5.6600 (-1.91%)
GUD.TO : 7.58 (-1.04%)
TXMD : 2.67 (+3.09%)
Knight Therapeutics and SIFI S.p.A. Announce Approval of NETILDEX(TM) in Canada

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, and SIFI S.p.A. ("SIFI"), a prominent Italian Eye Care company, today announced that Health Canada has...

KHTRF : 5.6600 (-1.91%)
GUD.TO : 7.58 (-1.04%)
Knight Therapeutics to Acquire Grupo Biotoscana, Establishing a Latin American Growth Platform

Transformational acquisition establishes Knight as a premiere pan-American (ex-US) specialty pharma company

KHTRF : 5.6600 (-1.91%)
GUD.TO : 7.58 (-1.04%)
Medison Urges Knight Therapeutics and Jonathan Goodman to Aggressively Pursue Opportunities Created by Distressed Opioid Case Targets

Medison Biotech (1995) Ltd. ("Medison"), which together with its affiliates owns more than 10.4 million shares or 7.5% of Knight Therapeutics, Inc. (TSX:GUD) ("Knight" or the "Company"), today commented...

KHTRF : 5.6600 (-1.91%)
GUD.TO : 7.58 (-1.04%)
Israeli Courts Rule Against Knight Therapeutics' and Jonathan Goodman in Frivolous and Costly Litigation Aimed at Silencing Medison

Medison Biotech (1995) Ltd. ("Medison"), which together with its affiliates owns more than 10.4 million shares or 7.5% of Knight Therapeutics, Inc. (TSX:GUD) ("Knight" or the "Company"), received a favorable...

KHTRF : 5.6600 (-1.91%)
GUD.TO : 7.58 (-1.04%)
Medison Expresses Concerns over Knight Therapeutics' Second Quarter Results and Demands Answers to Critical Questions from Jonathan Goodman

PETACH TIKVA, Israel , Aug. 9, 2019 /CNW/ - Medison Biotech (1995) Ltd. (" Medison "), which together with its affiliates owns more than 10.4 million shares or 7.5% of Knight Therapeutics, Inc....

GUD.TO : 7.58 (-1.04%)
Medison Expresses Concerns over Knight Therapeutics' Second Quarter Results and Demands Answers to Critical Questions from Jonathan Goodman

Medison Biotech (1995) Ltd. ("Medison"), which together with its affiliates owns more than 10.4 million shares or 7.5% of Knight Therapeutics, Inc. (TSX:GUD) ("Knight" or the "Company"), demands answers...

KHTRF : 5.6600 (-1.91%)
GUD.TO : 7.58 (-1.04%)
Knight Therapeutics Reports Second Quarter 2019 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2019. All dollar amounts are in thousands...

KHTRF : 5.6600 (-1.91%)
GUD.TO : 7.58 (-1.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Key Turning Points

2nd Resistance Point 7.72
1st Resistance Point 7.65
Last Price 7.58
1st Support Level 7.52
2nd Support Level 7.46

See More

52-Week High 8.88
Fibonacci 61.8% 8.20
Fibonacci 50% 7.99
Fibonacci 38.2% 7.78
Last Price 7.58
52-Week Low 7.10

See More

Business Summary

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada...

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar